NasdaqCM - Nasdaq Real Time Price USD
Corcept Therapeutics Incorporated (CORT)
At close: 4:00 PM EST
After hours: 5:55 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
628,555.00
482,375.00
401,858.00
365,978.00
353,874.00
Cost of Revenue
9,803.00
6,481.00
5,385.00
5,281.00
5,582.00
Gross Profit
618,752.00
475,894.00
396,473.00
360,697.00
348,292.00
Operating Expense
475,394.00
368,612.00
283,839.00
236,220.00
220,090.00
Operating Income
143,358.00
107,282.00
112,634.00
124,477.00
128,202.00
Net Non Operating Interest Income Expense
22,984.00
17,275.00
3,557.00
529.00
3,400.00
Pretax Income
166,342.00
124,557.00
116,191.00
125,006.00
131,602.00
Tax Provision
24,524.00
18,417.00
14,773.00
12,494.00
25,591.00
Net Income Common Stockholders
140,487.00
105,496.00
101,288.00
112,512.00
106,011.00
Diluted NI Available to Com Stockholders
140,487.00
105,496.00
101,288.00
112,512.00
106,011.00
Basic EPS
1.36
1.02
0.95
0.97
0.92
Diluted EPS
1.26
0.94
0.87
0.89
0.85
Basic Average Shares
102,930.75
103,560.00
106,787.00
115,653.00
115,412.00
Diluted Average Shares
111,379.75
111,742.00
115,966.00
125,963.00
124,194.00
Total Operating Income as Reported
143,358.00
107,282.00
112,634.00
124,477.00
128,202.00
Total Expenses
485,197.00
375,093.00
289,224.00
241,501.00
225,672.00
Net Income from Continuing & Discontinued Operation
141,818.00
106,140.00
101,418.00
112,512.00
106,011.00
Normalized Income
141,818.00
106,140.00
101,418.00
112,512.00
106,011.00
Interest Income
22,984.00
17,275.00
3,557.00
529.00
3,400.00
Net Interest Income
22,984.00
17,275.00
3,557.00
529.00
3,400.00
EBIT
143,358.00
107,282.00
112,634.00
124,477.00
128,202.00
EBITDA
144,506.00
109,644.00
116,080.00
127,953.00
130,439.00
Reconciled Cost of Revenue
9,803.00
6,481.00
5,385.00
5,281.00
5,582.00
Reconciled Depreciation
1,148.00
2,362.00
3,446.00
3,476.00
2,237.00
Net Income from Continuing Operation Net Minority Interest
141,818.00
106,140.00
101,418.00
112,512.00
106,011.00
Normalized EBITDA
144,506.00
109,644.00
116,080.00
127,953.00
130,439.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
12/31/2020 - 4/14/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CPRX Catalyst Pharmaceuticals, Inc.
21.48
+1.70%
TBPH Theravance Biopharma, Inc.
9.47
-1.46%
EXEL Exelixis, Inc.
35.61
+2.24%
ADMA ADMA Biologics, Inc.
21.18
-0.56%
MDGL Madrigal Pharmaceuticals, Inc.
347.45
+5.53%
CYTK Cytokinetics, Incorporated
49.10
+3.00%
HALO Halozyme Therapeutics, Inc.
49.00
+7.22%
UTHR United Therapeutics Corporation
372.89
+1.51%
LGND Ligand Pharmaceuticals Incorporated
119.19
+2.27%
VERA Vera Therapeutics, Inc.
48.31
+2.72%